USRE40640EExpiredUtility

Injectable microfoam containing a sclerosing agent

Assignee: BTG INT LTDPriority: Jun 23, 1993Filed: Sep 15, 2004Granted: Feb 17, 2009
Est. expiryJun 23, 2013(expired)· nominal 20-yr term from priority
A61P 9/14A61K 31/08A61K 9/122Y10S424/07
69
PatentIndex Score
6
Cited by
143
References
40
Claims

Abstract

Injectable microfoam for scleroteraphy. The sclerotherapy of varices is based on the injection of liquid substances capable of suppressing them. The present invention relates to the preparation of sclerosing substances in the form of a microfoam. The microfoam is prepared with sclerosing agents, and is then injected in the vein to be treated, so that the microfoam displaces the blood contained in the vein and provides for the contact of the sclerosing agent with the vascular endothelium, with a predetermined known concentration and during a controllable time.

Claims

exact text as granted — not AI-modified
1. Prepared or extemporaneously prepared injectable microfoam for therapeutic uses characterized in that the microfoam is prepared with any sclerosing substance. 
     
     
       2. Injectable microfoam for therapeutic uses, according to  claim 1 , characterized in that the sclerosing substance is polydocanol. 
     
     
       3. Injectable microfoam for therapeutic uses, according to  claim 1 , characterized in that the sclerosing substance is sodium tetradecyl sulfate. 
     
     
       4. Injectable microfoam for therapeutic uses, according to  claim 1 , characterized in that the sclerosing substance is a hypertonic glucostated or glucosaline solution. 
     
     
       5. Injectable microfoam for therapeutic uses, according to  claim 1 , characterized in that the sclerosing substance used is chromated glycerol. 
     
     
       6. Injectable microfoam for therapeutic uses, according to  claim 1 , characterized in that the sclerosing substance used is ethanolamine oleate. 
     
     
       7. Injectable microfoam for therapeutic uses, according to  claim 1 , characterized in that the sclerosing substance used is sodium morrhuate. 
     
     
       8. Injectable microfoam for therapeutic uses, according to  claim 1 , characterized in that the sclerosing substance used is any iodated solution. 
     
     
       9. A method for phlebologic treatment comprising injecting the microfoam of  claim 1  into vessels to be treated. 
     
     
       10. A method for phlebologic treatment comprising injecting the microfoam of  claim 2  into vessels to be treated. 
     
     
       11. A method for phlebologic treatment comprising injecting the microfoam of  claim 3  into vessels to be treated. 
     
     
       12. A method for treatment of esophageal varices comprising injecting the microfoam of  claim 1  into vessels to be treated. 
     
     
       13. A method for treatment of esophageal varices comprising injecting the microfoam of  claim 2  into vessels to be treated. 
     
     
       14. A method for treatment of esophageal varices comprising injecting the microfoam of  claim 3  into vessels to be treated. 
     
     
       15. A method for proctologic treatment comprising injecting the microfoam of  claim 1  into vessels to be treated. 
     
     
       16. A method for proctologic treatment comprising injecting the microfoam of  claim 2  into vessels to be treated. 
     
     
       17. A method for proctologic treatment comprising injecting the microfoam of  claim 3  into vessels to be treated. 
     
     
       18. A method for angiologic treatment comprising injecting the microfoam of  claim 1  into vessels to be treated. 
     
     
       19. A method for angiologic treatment comprising injecting the microfoam of  claim 2  into vessels to be treated. 
     
     
       20. A method for angiologic treatment comprising injecting the microfoam of  claim 3  into vessels to be treated. 
     
     
       21. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising
   at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and        a gas component, wherein the gas component consists essentially of oxygen or a mixture of oxygen and carbon dioxide.     
     
     
       22. The injectable microfoam of  claim 21 , wherein the at least one sclerosing substance is polidocanol. 
     
     
       23. The injectable microfoam of  claim 21 , wherein the microfoam further comprises at least one substance with a foaming capacity. 
     
     
       24. The injectable microfoam of  claim 21 , wherein the at least one sclerosing substance is sodium tetradecyl sulfate. 
     
     
       25. The injectable microfoam of  claim 23 , wherein the at least one substance with a foaming capacity is chosen from polysorbate  20 , polysorbate  80 , and polygeline. 
     
     
       26. A method of phlebologic treatment comprising
   injecting an effective amount of a prepared or extemporaneously prepared injectable microfoam into a vessel in need of phlebologic treatment,        wherein said injectable microfoam comprises at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and        a gas component, wherein the gas component consists essentially of oxygen or a mixture of oxygen and carbon dioxide.     
     
     
       27. The method of  claim 26 , wherein the at least one sclerosing substance is ploidocanol. 
     
     
       28. The method of  claim 26 , wherein the microfoam further comprises at least one substance with a foaming capacity. 
     
     
       29. The method of calim  26 , wherein the at least one sclerosing substance is sodium tetradecyl sulfate. 
     
     
       30. The method of  claim 26 , wherein the at least one substance with a foaming capacity is chosen from polysorbate  20 , polysorbate  80 , and polygeline. 
     
     
       31. A method of angiologic treatment comprising
   injecting an effective amount of a prepated or extemporaneously prepared injectable microfoam into a vessel in need of angiologic treatment,        wherein said injectable microfoam comprises at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhyatem and iodated solutions, and        a gas component, wherein the gas component consists essentially of oxygen or a mixture of oxygen and carbon dioxide.     
     
     
       32. The method of  claim 31 , wherein the at least one sclerosing substance is polidocanol. 
     
     
       33. The method of  claim 31 , wherein the microfoam further comprises at least one substance with a foaming capacity. 
     
     
       34. The method of  claim 31 , wherein the at least one sclerosing substance is sodium tetradecyl sulfate. 
     
     
       35. The method of  claim 33 , wherein the at least one substance with a foaming capacity is chosen from polysorbate  20 , polysorbate  80 , and polygeline. 
     
     
       36. A method of treating esophageal varices comprising
   injecting an effective amount of a prepared or extemporaneously prepared injectable microfoam into a vessel in need of such treatment,        wherein said injectable microfoam comprises at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and        a gas component, wherein the gas component consists essentially of oxygen or an mixture of oxygen and carbon dioxide.     
     
     
       37. The method of  claim 36 , wherein the at least one sclerosing substance is polidocanol. 
     
     
       38. The method of  claim 36 , wherein the microfoam futher comprises at least one substance with a foaming capacity. 
     
     
       39. The method of  claim 36 , wherein the at least one sclerosing substance is sodium tetradecyl sulfate. 
     
     
       40. The method of  claim 38 , wherein the at least one substance with a foaming capacity is chosen from polysorbate  20 , polysorbate  80 , and polygeline.

Join the waitlist — get patent alerts

Track USRE40640E — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.